Donga ST Wins Minister of Health and Welfare Award for "Innovative Pharmaceutical Company"

Received Overall A Grade in ESG Evaluation

Donga ST announced on December 2 that it received the Minister of Health and Welfare Award for "Innovative Pharmaceutical Company" at the "2025 Health Industry Performance Exchange" held on November 28.

Exterior view of Donga ST headquarters in Dongdaemun-gu, Seoul. Donga ST

This event was hosted by the Ministry of Health and Welfare and organized by the Korea Health Industry Development Institute. Each year, the award recognizes companies among innovative pharmaceutical firms that have contributed to public health improvement and industry development. The Innovative Pharmaceutical Company certification is a government program that evaluates and certifies domestic pharmaceutical companies with R&D-driven innovation capabilities, such as new drug development and platform technology establishment.

Donga ST has focused on developing innovative new drugs to address unmet medical needs for patients and the medical community. The company has developed its own new drugs such as Zydena, Suganon, and Sivextro, as well as natural medicines like Stillen and Motilitone. It is currently concentrating research on treatments for metabolic diseases such as diabetes, obesity, and MASH (metabolic dysfunction-associated steatohepatitis). Donga ST is also expanding its R&D investment through initiatives such as establishing the Songdo Bio Research Institute and acquiring Aptys, which supports research into next-generation antibody-drug conjugate (ADC) platform drugs.

To enhance customer satisfaction, Donga ST launched diabetes combination drugs Sugadapa and Sugatri Extended Release, which improve medication convenience for patients. The company has also worked to improve customer satisfaction through various innovative initiatives, including preparing for domestic approval and supply of the epilepsy drug Xcopri, introducing e-labels for pharmaceuticals, and implementing QbD (Quality by Design) for pharmaceuticals. As a result of these efforts, Donga ST has been awarded the CCM (Consumer-Centered Management) certification for four consecutive years, recognizing its achievements in consumer-friendly management.

Since 2019, Donga ST has operated a social committee to fulfill its corporate social responsibility. The company engages in various social contribution activities, such as donating growth hormone for children with short stature and providing financial support for anticancer drugs to low-income patients. Donga ST also contributes to public health by ensuring a stable supply of withdrawal-prevention medicines and nationally essential medicines.

Thanks to these efforts, Donga ST received an overall A grade in ESG evaluation. The company has also strengthened its compliance and sustainable management systems by operating a CP (Compliance Program), obtaining ISO 37001 (Anti-Bribery Management System) certification, and achieving an A grade in CP rating evaluation. In addition, Donga ST has been recognized for its positive environmental management practices, including being selected as an excellent company for work-life balance and establishing solar power facilities.

A Donga ST representative stated, "This award recognizes our efforts to improve public health and advance the pharmaceutical industry through R&D capabilities centered on new drugs, global business achievements, and social responsibility. We will continue to prioritize public health improvement and pharmaceutical industry development as our core values and faithfully fulfill our role as an innovative pharmaceutical company."

This content was produced with the assistance of AI translation services.